Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Shepardson D, Marks SM, Chesson H, Kerrigan A, Holland DP, Scott N, Tian X, Borisov AS, Shang N, Heilig CM, Sterling TR, Villarino ME, Mac Kenzie WR
Int J Tuberc Lung Dis. 2013 17 (12): 1531-7

PMID: 24200264 · PMCID: PMC5451112 · DOI:10.5588/ijtld.13.0423

MeSH Terms (17)

Antitubercular Agents Computer Simulation Cost-Benefit Analysis Directly Observed Therapy Drug Administration Schedule Drug Costs Drug Therapy, Combination Hospital Costs Humans Isoniazid Latent Tuberculosis Models, Economic Quality-Adjusted Life Years Rifampin Time Factors Treatment Outcome United States

Connections (1)

This publication is referenced by other Labnodes entities: